Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection.
Yu-Fen TsaiYi-Chang LiuChing-I YangTzer-Ming ChuangYa-Lun KeTsung-Jang YehYuh-Ching GauJeng-Shiun DuHui-Ching WangShih-Feng ChoChin-Mu HsuPey-Fang WuChing-I HuangChung-Feng HuangMing-Lung YuChia-Yen DaiHui-Hua HsiaoPublished in: Journal of personalized medicine (2021)
Inferior survival of HCV-positive DLBCL was observed and associated with poor performance status, higher numbers of complications, and intolerance of treatment, leading to fewer therapy. Therefore, anti-HCV therapy, such as direct-acting antiviral agents, might benefit these patients in the future.
Keyphrases
- diffuse large b cell lymphoma
- poor prognosis
- hepatitis c virus
- end stage renal disease
- epstein barr virus
- long non coding rna
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- human immunodeficiency virus
- risk factors
- mesenchymal stem cells
- current status
- cell therapy
- replacement therapy
- antiretroviral therapy